Mounjaro Vs Ozempic - Guide | Cured Pharmacy

Mounjaro Vs Ozempic

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From £145.00£124.99UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 17 June 2026

Last Updated: 12 August 2026

Trying to decide between Mounjaro and Ozempic for weight loss is one of the most common questions people ask in 2026, and it is completely understandable given how dramatically the injectable weight loss landscape has changed over the past few years. Both medications have genuine clinical evidence behind them, both are available in the UK, and both work by influencing the hormones that control appetite and blood sugar — but they are not the same drug, they do not work in exactly the same way, and the results they produce can differ quite significantly from person to person.

Quick Summary

Both Mounjaro (tirzepatide) and Ozempic (semaglutide) are injectable medications used for weight management in the UK. Mounjaro acts on two hormonal receptors simultaneously, while Ozempic targets just one, which may partly explain why clinical trials show Mounjaro typically produces greater average weight loss over the same treatment period.

  • Mounjaro (tirzepatide) targets both GIP and GLP-1 receptors; Ozempic (semaglutide) targets GLP-1 only
  • Clinical trials show Mounjaro users can lose up to 22.5% of body weight versus around 15% with semaglutide
  • Both are given as once-weekly subcutaneous injections using a pre-filled pen device
  • Side effect profiles are similar, though individual tolerance varies considerably
  • Ozempic is licensed for type 2 diabetes in the UK; Mounjaro holds both diabetes and weight management licences

⚖️ Mounjaro vs Ozempic: Weight Loss Estimator

Enter your current weight and select your medication to estimate potential weight loss over 12 months. This is for educational purposes only and not a medical prediction.

*Based on published SURMOUNT and STEP trial averages. Individual results vary. Always consult a UK prescriber.

Table of Contents

How Mounjaro and Ozempic Work Differently

When people start researching Mounjaro vs Ozempic, the first question is usually "aren't they basically the same thing?" The honest answer is no — not quite. While both belong to a broader category of hormonal weight loss treatments, they act on different combinations of receptors in the body, and that distinction has real consequences for how well they work.

Ozempic contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the GLP-1 hormone that your gut naturally releases after eating. This signals to your brain that you are full, slows gastric emptying, and reduces the urge to eat. It also stimulates insulin release in response to blood glucose, which is why it was originally developed for type 2 diabetes management. For people looking to support healthy weight management alongside other lifestyle options such as XLS Medical Weight Loss supplements, understanding how these mechanisms differ is genuinely useful.

Mounjaro, on the other hand, contains tirzepatide. It is what scientists call a dual agonist — meaning it activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously. GIP is another gut hormone involved in fat metabolism and appetite regulation. The theory is that activating both pathways creates a more powerful and complementary appetite-suppressing effect than targeting GLP-1 alone. This dual action is widely considered to be the core reason why Mounjaro consistently outperforms semaglutide in head-to-head comparisons in terms of average weight loss.

  • Ozempic = GLP-1 receptor agonist only (semaglutide)
  • Mounjaro = GLP-1 + GIP dual receptor agonist (tirzepatide)
  • Both reduce appetite, slow stomach emptying, and improve blood sugar control
  • The dual mechanism of Mounjaro is believed to drive superior weight loss outcomes
  • Neither is a stimulant or appetite suppressant in the traditional pharmacological sense

Mounjaro vs Ozempic: Weight Loss Results Compared

For most people, the headline question when comparing these two medications is simple: which one produces more weight loss? Looking at the clinical trial data, the picture is fairly clear. The SURMOUNT-1 trial — which studied tirzepatide (Mounjaro) in adults with obesity — found that participants lost an average of 20.9% of their body weight at the highest 15mg dose over 72 weeks. Some individuals lost as much as 22.5% of their starting body weight, which is a figure that was genuinely unprecedented for a non-surgical intervention at the time.

By comparison, the STEP-1 trial for semaglutide (the active ingredient in Ozempic and Wegovy) showed an average weight loss of around 14.9% over 68 weeks at the 2.4mg weekly dose. That is still a highly significant and clinically meaningful result, and one that changed the treatment landscape for obesity in the UK. But on average, the tirzepatide arm of Mounjaro vs Ozempic comparisons consistently shows a greater percentage of body weight lost.

It is worth stressing that average figures do not tell the whole story. Individual response to either medication can vary widely based on genetics, diet quality, physical activity, and whether you have underlying conditions like insulin resistance or polycystic ovary syndrome. Some people respond exceptionally well to Ozempic and plateau with Mounjaro. Others see rapid results with Mounjaro that far exceed the trial averages. A prescriber who understands your full health history is best placed to help you predict which direction your response might go.

  • Mounjaro average weight loss: up to 22.5% of body weight (SURMOUNT-1, 72 weeks)
  • Ozempic/semaglutide average weight loss: up to 14.9% of body weight (STEP-1, 68 weeks)
  • Both produce significantly more weight loss than lifestyle changes alone
  • Individual variation is considerable — some people do better on one than the other
  • Results require sustained use alongside healthy diet and activity habits

Side Effects You Should Know About

One of the most common concerns people raise when looking at Mounjaro vs Ozempic is around tolerability and side effects. Both medications share a similar side effect profile because they both influence GLP-1 receptors — so the types of reactions people experience tend to overlap significantly.

The most frequently reported side effects with both drugs are gastrointestinal in nature. Nausea is the most common, especially during the dose escalation phase. Vomiting, diarrhoea, constipation, abdominal discomfort, and a reduced appetite that goes beyond the intended effect are all possible. These side effects tend to be most pronounced in the first few weeks at each new dose level and often settle as the body adjusts. Starting on a low dose and titrating up slowly — which is the standard protocol for both medications — is specifically designed to minimise these early side effects.

There is some evidence that Mounjaro may produce slightly more pronounced gastrointestinal effects at higher doses compared to Ozempic, though this varies between individuals. Injection site reactions such as redness, bruising, or mild swelling are possible with both. More serious but rare side effects include pancreatitis, gallbladder problems, and a theoretical risk of thyroid C-cell tumours that has been observed in animal studies — though this has not been confirmed in human clinical populations. Both medications carry this warning in their UK product information. If you notice severe abdominal pain, you should stop the medication and seek urgent medical advice.

  • Nausea, vomiting, diarrhoea, and constipation are the most common side effects
  • Side effects are typically worst during dose increases and improve with time
  • Injection site reactions are usually mild and short-lived
  • Pancreatitis is a rare but serious risk — seek urgent help for severe stomach pain
  • Both medications are contraindicated in pregnancy and personal or family history of medullary thyroid carcinoma

Dosing, Administration, and Titration Schedules

Both Mounjaro and Ozempic are given as once-weekly subcutaneous injections, meaning they go into the fatty tissue just under the skin — typically the abdomen, thigh, or upper arm. Both come in pre-filled pen devices that are designed to make self-injection as straightforward as possible, even for people who have never injected themselves before. Many people are anxious about this aspect before they start, but the vast majority find it manageable within the first few uses.

The titration schedules differ between the two medications. Mounjaro starts at 2.5mg once weekly for four weeks, then increases to 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg — each step held for at least four weeks before increasing. This graduated approach is important. Rushing the escalation is one of the most common reasons people experience excessive nausea. Ozempic for weight loss (as Wegovy, semaglutide 2.4mg) follows a similarly stepped schedule, starting at 0.25mg weekly and increasing gradually to the maintenance dose of 2.4mg over approximately 16 weeks.

For people who are also managing weight loss alongside other approaches, understanding that these medications require patience during the dose build phase is essential. The full weight loss benefit is usually not seen until you reach and maintain the higher therapeutic doses. Missing injections should be managed carefully — if you miss a dose by fewer than four days, you can take it as soon as you remember. If it has been longer, skip that dose and take the next one on your scheduled day.

  • Both are once-weekly subcutaneous injections via pre-filled pen devices
  • Mounjaro starts at 2.5mg, titrating up to a maximum of 15mg weekly
  • Ozempic (as Wegovy for weight loss) starts at 0.25mg, reaching 2.4mg maintenance
  • Each dose step is held for at least four weeks before increasing
  • Inject on the same day each week for consistency and best results

Who Should Choose Which Medication?

This is probably the most practically useful question when evaluating Mounjaro vs Ozempic, and the answer is not one-size-fits-all. Your medical history, current health status, what you have already tried, and your personal weight loss goals all factor into which medication is likely to be the better fit for you.

Mounjaro is likely to be the preferred option if you are looking for the maximum available weight loss from a licensed injectable treatment, particularly if you have a higher BMI, have not responded sufficiently to Ozempic or other GLP-1 medications in the past, or if you have type 2 diabetes that also needs better control. In 2026, Mounjaro holds an MHRA licence specifically for chronic weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related health condition — making it one of the most broadly applicable options currently available.

Ozempic may be the more appropriate starting point if you are in the earlier stages of a weight management journey, if your GP has already prescribed it for type 2 diabetes management, or if cost is a significant consideration. It has a longer track record in clinical practice globally and may be more familiar to prescribers managing complex diabetes cases. People who have tried Alli weight loss capsules or other non-injectable options without sufficient results often find either injectable treatment to be a meaningful step up. Those with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 should not use either medication.

  • Choose Mounjaro if you want maximum weight loss potential from a licensed UK treatment
  • Choose Mounjaro if you have previously not responded well to semaglutide-based treatments
  • Consider Ozempic if you have type 2 diabetes and your GP is already managing that condition
  • Neither is suitable during pregnancy, breastfeeding, or with a history of certain thyroid cancers
  • A prescriber assessment is essential before starting either medication

Cost and Availability in the UK

Cost is a real and legitimate concern for anyone considering injectable weight loss treatment in the UK. NHS prescriptions for weight loss purposes remain limited and subject to specific eligibility criteria, which means most people are accessing these medications through private prescriptions. Understanding the pricing landscape helps you plan and budget realistically.

As of 2026, Mounjaro is available privately in the UK at prices that vary depending on dose and supplier. At Cured Pharmacy, Mounjaro (tirzepatide) KwikPen is available from From £145.00£124.99, with a 10% saving and the reassurance of a free private prescription issued by UK-based prescribers. Ozempic pricing varies similarly, though the cost per month can be comparable at higher doses. It is worth noting that Wegovy (semaglutide 2.4mg, the weight management licensed version) and Ozempic (semaglutide 1mg, licensed for type 2 diabetes) are technically different products even though they share the same active ingredient — and this distinction matters both clinically and from a prescribing perspective.

Availability has improved significantly over the past two years, though supply chain issues have periodically affected both products. Mounjaro is currently one of the more consistently available options in the UK private market. For people also exploring additional weight management products such as XLS Medical Direct Fat Binder sachets, it is worth discussing with your prescriber whether combining approaches is appropriate for your situation. Always ensure you are purchasing from a regulated UK pharmacy with verified prescribers.

  • Mounjaro is available privately from From £145.00£124.99 per pen at Cured Pharmacy
  • Ozempic and Wegovy prices are broadly comparable on a monthly basis
  • NHS eligibility for weight management injectables remains restricted in 2026
  • Always use a regulated UK pharmacy with GPhC-registered prescribers
  • Free private prescriptions are included through Cured Pharmacy's assessment process

Full Comparison Table: Mounjaro vs Ozempic

Feature Mounjaro (Tirzepatide) Ozempic (Semaglutide)
Active ingredient Tirzepatide Semaglutide
Receptor targets GLP-1 + GIP (dual agonist) GLP-1 only
UK licence for weight loss Yes (MHRA approved) Wegovy (2.4mg) only — Ozempic is licensed for T2 diabetes
UK licence for type 2 diabetes Yes Yes
Average weight loss (trials) Up to 22.5% body weight Up to 14.9% body weight
Starting dose 2.5mg once weekly 0.25mg once weekly
Maximum dose 15mg once weekly 2.4mg once weekly (Wegovy for weight loss)
Injection frequency Once weekly Once weekly
Common side effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation
Private prescription cost (approx.) From From £145.00£124.99 per pen Varies by dose and supplier
Suitable for BMI ≥30, or ≥27 with weight-related condition BMI ≥30, or ≥27 with weight-related condition (Wegovy)
Manufacturer Eli Lilly Novo Nordisk

Key Takeaways

  • Mounjaro (tirzepatide) targets two hormonal receptors — GLP-1 and GIP — giving it a mechanistic advantage over Ozempic's single GLP-1 action, which likely explains its consistently greater average weight loss in clinical trials
  • Clinical evidence shows Mounjaro produces up to 22.5% body weight loss versus approximately 14.9% with semaglutide, though individual results vary considerably based on dose, adherence, and lifestyle factors
  • Both medications share a similar side effect profile dominated by gastrointestinal symptoms, which are most pronounced during dose escalation and typically improve with time
  • Ozempic is licensed specifically for type 2 diabetes in the UK; Mounjaro holds licences for both type 2 diabetes and chronic weight management — an important distinction for prescribing purposes
  • Always access either medication through a registered UK pharmacy with qualified prescribers — and use the full titration schedule to minimise side effects and maximise long-term results

When to Seek Professional Advice

If you are considering starting either Mounjaro or Ozempic, the first step should always be a proper clinical assessment with a qualified prescriber. These are prescription-only medications for good reason — they have meaningful effects on hormonal and metabolic pathways, and they interact with certain conditions and medications in ways that require professional evaluation.

You should seek medical advice promptly if you experience any of the following while taking either medication: severe or persistent abdominal pain (which may indicate pancreatitis), signs of an allergic reaction such as swelling of the face or difficulty breathing, significantly worsening vision, symptoms of low blood sugar including shakiness or confusion (particularly if you are also taking other diabetes medications), or any unusual changes in mood or behaviour. If you are pregnant, planning to become pregnant, or breastfeeding, you should not use either medication and should speak to your GP or midwife about safe alternatives.

For people managing other health conditions alongside weight issues — including thyroid disorders, for which a Newfoundland Thyroid Test may be informative before starting treatment — a comprehensive health review before beginning injectable weight loss therapy is particularly important. Your prescriber can also review any other medications you are taking to check for interactions and help you choose the approach most likely to work safely for your individual circumstances.

Scientific References

  1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022 (SURMOUNT-1 Trial) [Accessed 12 August 2026]
  2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The Lancet Diabetes & Endocrinology, 2021 (STEP-1 Trial) [Accessed 12 August 2026]
  3. Medicines and Healthcare products Regulatory Agency (MHRA). Mounjaro (tirzepatide) — UK Product Information and Prescribing Guidance, 2023 [Accessed 12 August 2026]
  4. NICE Technology Appraisal TA994: Tirzepatide for managing overweight and obesity in adults, NICE, 2024 [Accessed 12 August 2026]
  5. NICE Technology Appraisal TA864: Semaglutide for managing overweight and obesity in adults, NICE, 2023 [Accessed 12 August 2026]
  6. Mounjaro (tirzepatide) Summary of Product Characteristics, Eli Lilly, Electronic Medicines Compendium, 2023 [Accessed 12 August 2026]
  7. Frías JP et al., Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2), The Lancet, 2021 [Accessed 12 August 2026]
  8. NICE Guideline NG28: Type 2 diabetes in adults: management, NICE, 2022 (updated) [Accessed 12 August 2026]
  9. Diabetes UK Position Statement: Treatment targets in type 2 diabetes, Diabetes UK, 2023 [Accessed 12 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My Assessment Returning Customer? Log In to Your Account

Frequently Asked Questions

How long does it take to see results with Mounjaro or Ozempic?

How long it takes to see results varies between the two. With Mounjaro, most people notice appetite suppression within the first two to four weeks, with meaningful weight loss typically visible by week eight to twelve. Ozempic users often report similar early changes, though average total weight loss tends to be lower over the same treatment period.

Is Mounjaro safe to use long term in the UK?

Mounjaro is considered safe for long-term use when prescribed by a qualified UK clinician and used under regular review. It was approved by the MHRA for chronic weight management in adults, and as of 2026 it remains one of the most extensively studied injectable weight loss treatments available on the UK market.

Can you switch from Ozempic to Mounjaro?

Switching from Ozempic to Mounjaro is possible and is something many UK clinicians are now doing in 2026. Because both drugs act on overlapping hormonal pathways, a structured transition is usually recommended rather than an abrupt swap. Your prescriber will advise on timing, dose adjustment, and what to watch for during the changeover period.

What is the maximum dose of Mounjaro for weight loss?

The maximum approved dose of Mounjaro for weight loss is 15mg once weekly, reached gradually over a titration schedule that typically starts at 2.5mg. The stepwise increase helps the body adjust and reduces the likelihood of gastrointestinal side effects such as nausea, vomiting, or diarrhoea during the early weeks of treatment.

Back to blog